BRIDGEWATER, NJ, July 25, 2023 /CNW/ - After making strides in environmental sustainability and social impact commitments, Sanofi Consumer Healthcare North America is pleased to announce it has earned B Corp Certification. This designation follows a rigorous evaluation and is the first time such certification has been granted to a large consumer healthcare company. Sanofi Consumer Healthcare North America has products in nearly 54 million households in the U.S and Canada, including Allegra®, Icy Hot®, Dulcolax® and Unisom®.
Businesses certified by B Lab, a third-party non-profit, are leaders in the global movement for an equitable, sustainable economy. B Lab measures a company's entire social and environmental impact and attaining B Corp Certification means a company meets high standards of social and environmental performance, accountability, and transparency.
Head of North America Consumer Healthcare, Sanofi
"We are honored to join the B Corp movement alongside other companies aiming to transform business into a force for good. A recent study by NielsenIQ found that 78 percent of US consumers say that a sustainable lifestyle is important to them1 and we are committed to meeting this demand by integrating sustainable practices into every aspect of our operations. Our B Corp Certification is another step in our journey to champion better self-care for a healthier society and a healthier planet."
Sanofi Consumer Healthcare North America earned B Corp Certification because of its continued commitment to social impact and sustainability, including:
Learn more about Sanofi Consumer Healthcare North America's B Corp Certification here.
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, sustainable and environmental goals, other ESG matters, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans", "strives", "ambition", "goal", "target" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, reputational issues related to ESG matters or our inability to reach our ESG goals, volatile economic, geopolitical, and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that pandemics or other global crisis may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2022. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
1 McKinsey & Company and NielsenIQ, 2023
SOURCE Sanofi-Aventis Canada Inc.